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ABSTRACT
Aims To estimate the effects of needle and syringe programmes (NSP) and opioid substitution therapy (OST), alone or in
combination, for preventing acquisition of hepatitis C virus (HCV) in people who inject drugs (PWID).Methods Systematic
review andmeta-analysis. Bibliographic databases were searched for studies measuring concurrent exposure to current OST
(within the last 6 months) and/or NSP and HCV incidence among PWID. High NSP coverage was deﬁned as regular NSP
attendance or ≥ 100% coverage (receiving sufﬁcient or greater number of needles and syringes per reported injecting
frequency). Studies were assessed using the Cochrane risk of bias in non-randomized studies tool. Random-effects models
were used in meta-analysis. Results We identiﬁed 28 studies (n = 6279) in North America (13), United Kingdom (ﬁve),
Europe (four), Australia (ﬁve) and China (one). Studies were at moderate (two), serious (17) critical (seven) and non-
assessable risk of bias (two). Current OST is associatedwith 50% [risk ratio (RR) =0.50, 95% conﬁdence interval (CI) = 0.40–
0.63] reduction in HCV acquisition risk, consistent across region and with low heterogeneity (I2 = 0, P = 0.889).
Weaker evidence was found for high NSP coverage (RR = 0.79, 95% CI = 0.39–1.61) with high heterogeneity
(I2 = 77%, P = 0.002). After stratifying by region, high NSP coverage in Europe was associated with a 56% reduction in
HCVacquisition risk (RR = 0.44, 95% CI = 0.24–0.80) with low heterogeneity (I2 = 12.3%, P = 0.337), but not in North
America (RR = 1.58, I2 = 89.5%, P =< 0.001). Combined OST/NSP is associated with a 74% reduction in HCVacquisition
risk (RR = 0.26, 95% CI = 0.07–0.89, I2 = 80% P = 0.007). According to Grades of Recommendation Assessment,
Development and Evaluation (GRADE) criteria, the evidence on OST and combined OST/NSP is low quality, while
NSP is very low. Conclusions Opioid substitution therapy reduces risk of hepatitis C acquisition and is strengthened
in combination with needle and syringe programmes (NSP). There is weaker evidence for the impact of needle syringe
programmes alone, although stronger evidence that high coverage is associated with reduced risk in Europe.
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INTRODUCTION
Hepatitis C virus (HCV) is a major global public health
concern, with approximately 114.9 (91.9–148.7) million
people having antibodies to HCV [1], 3–4 million people
newly infected each year and 350000 deaths occurring
annually [2,3]. People who inject drugs (PWID) are the
key at risk group in most high-income countries, and in
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most countries more than half of PWID have been infected
with HCV [4].
Evidence shows that injecting with needles and
syringes used previously by someone else is the main risk
factor for infection with HIVand HCVamong PWID [5,6].
Additional risks for HCV acquisition in this population
include sharing drug preparation containers, ﬁlters, rinse
water and backloading (a method of sharing drugs by
transferring them from the needle of one syringe into
the barrel of another) [5,6]. The provision of sterile
injecting equipment through needle and syringe
programmes (NSP) and enrolment in opioid substitution
treatment (OST) are among the primary interventions
for reducing HCV and HIV transmission among PWID.
NSPs provide sterile needles and syringes and other
injecting equipment to PWID via ﬁxed-sites, outreach,
peer networks, vending machines and pharmacies. By
maximizing the amount of sterile injecting equipment (in-
cluding syringes, cookers, cottons) in circulation, the time
infected equipment remains in circulation decreases and
the proportion of unsafe injections or the need to share
equipment to prepare drugs reduces [7]. OST is prescribed
to dependent opioid users to diminish the use and effects
of illicitly acquired opioids and reduce the frequency of
injection and exposure to unsafe injecting practices [8].
The most commonly prescribed forms of OST are opiate
agonist treatments—methadone maintenance therapy
and buprenorphine maintenance treatment. NSPs and
OST are often the ﬁrst point of service contact for PWID
and so they provide referrals and support to other social
and welfare services.
There is good evidence that NSP and OST in combina-
tion reduce injecting risk behaviours and some evidence of
an impact on HIV incidence. However, evidence for
their impact on HCV incidence among PWID is limited
[9–15]. Recent reviews have estimated a moderate effect
of NSPs in reducing HIV transmission by 48% [95%
conﬁdence interval (CI) = 3–72%] and strong evidence for
OST reducing HIV transmission by 54% (95%
CI = 33–68%) [16,17]. Previous evidence syntheses for
use of NSPs have focused primarily on HIV as the main
outcome and, as a consequence, failed to include all the
available evidence on HCV [8,11,13,18]. Another review
that measured the effect of NSP use did not include a
meta-analysis due to heterogeneity in the measurement
of NSP exposure, and focused on evidence from North
America, limiting the generalizability of ﬁndings to other
settings, including Europe [19]. An analysis of pooled data
examined the effect of NSP coverage on HCV incidence
showed that high coverage of NSP (≥ 100% of injections
with a sterile syringe) or receipt of OST either currently
or within the past 6 months can each reduce HCV
infection risk by 50% and in combination by 80%. The
small number of incident HCV cases meant that the
efﬁcacy estimate for 100% NSP among those not on OST
was weak [20].
Evidence of the effect of NSP with and without OST on
HCV incidence is inconclusive [11]. There is a need to
strengthen this existing evidence base, including a more
reﬁned measure of coverage of NSP that accounts for
frequency and the degree to which the NSP meets
individuals’ requirement for needles and syringes in order
to inform interventions to reduce the burden of
HCV. We undertook a Cochrane Systematic Review and
meta-analysis of unpublished and published studies. Our
primary objective was to assess the impact of NSPs with
and without OSTon the incidence of HCV infection among
PWID. Our secondary objective involved estimating any
differential effect of variables including duration of
treatment, geographical setting, study setting (i.e. commu-
nity, or treatment) and sample characteristics (such as age,
sex, experience of prison, homelessness, use of stimulant
injection). Full methods are reported in the Cochrane
Review [21].
METHODS
Search
We carried out two separate systematic search strategies.
The ﬁrst identiﬁed studies examined directly the impact of
OST or NSP in relation to HCV incidence. The second
focused on identifying cohort studies that reported HCV
incidence among PWID. These studies were examined to
identify whether they reported the impact of OST or NSP
in relation to HCV transmission in secondary analyses.
Where no measure was reported, authors of studies were
contacted and asked if OST or NSP exposures were
measured, and if so to provide unpublished data. The full
search terms are reported in the Cochrane Review [21].
Multiple databases were included up to March 2017
[Medline, PsycInfo, Embase, Cochrane Drug and Alcohol
Group Specialized Register, the Cochrane Database of
Systematic Reviews, the Database of Abstracts of Reviews
of Effectiveness, Global Health, Cinahl (EBSCO Host), Web
of Science], as well as conference abstracts of the Interna-
tional HIV/AIDS Society and the European Association
for the Study of Liver conference and the International
Symposium on Hepatitis Care in Substance Users. Grey
literature was searched from European Monitoring Centre
on Drugs and Drug Addiction and the European Centre
for Disease Control.
Study selection
Two reviewers screened full text copies of relevant articles
to determine whether they met eligibility criteria. There
was no language restriction.
2 Lucy Platt et al.
© 2017 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. Addiction
Data extraction and analysis
For the full data extraction form see the full Cochrane
Review [21], which included study design and recruit-
ment; sample characteristics; intervention; outcome mea-
sure and intervention effect. Data were double-extracted.
Eligibility criteria
We included all observational (prospective and retrospec-
tive cohorts, cross-sectional surveys and case–control
studies) or experimental studies that: (a) measured
exposure to either intervention against no intervention or
a reduced exposure and reported HCV incidence as an
outcome; and (b) reported a minimum of two seroconver-
sions. We included studies that measured incidence of
HCV in PWID via repeated testing, such as detection of
HCV RNA-positive among HCV-negative participants.
OST exposure was measured through self-report, deﬁned
as the use of prescribed methadone or buprenorphine
within the last 6 months. High NSP coverage was deﬁned
as obtaining 100% of needles and syringes from a safe
source, reporting obtaining ≥ 100% of sterile needles and
syringes per injecting frequency, regular attendance at
least once per week at an NSP or obtaining most needles
and syringes from an NSP during the last 6months.We ex-
cluded studies measuring HCV incidence using self-
reported data and those conducted in prison settings.
Risk of bias
We assessed the quality of included studies through the
Cochrane risk of bias assessment tool for non-randomized
studies of interventions [22]. This assesses studies accord-
ing to seven domains: confounding; selection bias;
measurement of interventions; departures from interven-
tion; missing data; measurement of outcomes; and
selection of reported results, to give an overall risk of bias
classiﬁed into four categories of low to critical. We decided
that minimum adjustment for confounding should include
time since ﬁrst injection or age and injecting frequency at
baseline. We assessed the overall quality of the evidence
for the primary outcome using the Grades of Recommen-
dation Assessment, Development and Evaluation (GRADE)
system [23]. We used funnel plots (plots of the effect
estimate from each study against the sample size or effect
standard error) to assess the potential for bias related to
the size of the studies, which could indicate possible
publication bias.
Summary measures and synthesis of results
We used a random-effects meta-analysis for the primary
analyses, allowing for heterogeneity between and within
studies. Effect estimates derived from studies adjusting for
confounders as well as those that did not (unadjusted
estimates) were pooled in separate meta-analyses. We
examined heterogeneity with the I2 statistic and identiﬁed
reasons for heterogeneity using univariable random-effects
meta-regression to compare subgroups by geographical
region of study; site of recruitment; proportion of female
participants; main drug injected; type of NSP; frequency
of injecting; and study design. We used sensitivity analyses
to determine to what extent the overall intervention effect
was changed by: the inclusion of studies at severe or
unclear risk of bias; the inclusion of studies that did not
adjust for confounders; exclusion of unpublished data sets;
and excluding cross-sectional studies that measured
intervention effect at baseline only.
RESULTS
The numbers of studies identiﬁed, reviewed and selected and
the reasons for exclusion for both searches are shown in
Fig. 1. We identiﬁed 21 published studies that directly
included measures of the impact of exposure to either OST
or NSP on HCV transmission [12,24–43]. In addition, we
identiﬁed 11 eligible prospective studies that measured
HCV incidence and contacted the authors of these papers
[44–54]. Of these, unpublished data were obtained from
cohort studies in Montreal (Canada) [Bruneau
(unpublished)]; Baltimore (USA) [Mehta (unpublished)],
San Francisco (USA) [Page (unpublished)], Sydney and
Melbourne (Australia) [55] [Maher (unpublished)], London
(UK) [Judd (unpublished)] and three cross-sectional
surveys in Bristol, Birmingham and Leeds (UK) [Hope
(unpublished)]. In total we included 1736 HCV incident
infections and 6513.04 person-years of follow-up. Overall
HCV incidence ranged between 5.9 and 42 cases per 100
person-years throughout the studies.
Description of studies
Table 1 summarizes the characteristics of the included
studies undertaken in the United States (n = 8), UK
(n = 5), Canada (n = 5), Australia (n = 5) and one study
each in the Netherlands, France, Italy, Spain and
China. Twenty-one of the included studies reported the
impact of OST [12,24,25,30,31,34,36–38,40–43,55,56]
[Bruneau (unpublished), Mehta (unpublished), Page
(unpublished), Maher (unpublished), Judd (unpublished),
Hope (unpublished)]. Seventeen studies reported the
impact of NSP [12,26–29,32,33,35,39,41,43] [Bruneau
(unpublished), Mehta (unpublished), Page (unpublished)].
Four studies assessed the impact of combined NSP with
OST [12,29,32] [Bruneau (unpublished)]. There were no
experimental studies. Sample size varied from 46 to 2788,
with participants recruited through street outreach,
respondent-driven sampling or service providers. Twenty-
OST and NSP to prevent HCV transmission 3
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ﬁve studies reported the sex of participants, of which 32%
(range = 2.8–55.9%) was the mean proportion of women
across the studies. Three were excluded from this analysis,
as they published only unadjusted estimates of life-time
use of OST versus never using OST [36,41,42].
Risk of bias
Risk of bias decisions are summarized in last column of
Table 1 and in the Supporting information, Table S1. Only
two studies were judged at moderate overall risk of bias
[38,40], 17 studies were judged as serious overall risk of
bias [24,26–33,37,39,41,43] [Bruneau (unpublished),
Maher (unpublished)] and seven were at critical risk
[25,34–36,42,55] [Judd (unpublished)]. For two studies
[Mehta (unpublished), Page (unpublished)], we did not
have enough information to make a judgement.
Current use of opioid substitution therapy
We pooled data from a total of 17 studies that measured
current OST [12,24,25,30–32,34,37,38,40,41,43],
including ﬁve unpublished estimates [55] [Bruneau
(unpublished), Maher (unpublished), Judd (unpublished),
Hope (unpublished)]. Twelve studies (6361 participants)
presented adjusted measures, on which the primary analy-
ses were focused [24,30,31,34,38,40,43,56] [Bruneau
(unpublished), Mehta (unpublished), Maher (unpub-
lished), Judd (unpublished)]. Random-effect meta-analysis
of multivariable estimates showed that OST was associated
with a 50% reduction in the risk of HCV infection [risk ratio
(RR) = 0.50] with little heterogeneity between studies
(I2 = 0, P = 0.889).
This effect was maintained when the analysis was
limited to exclude two studies judged to be at critical risk
of bias [34] [Judd (unpublished)] and one study where
Figure 1 Flow-chart of included studies
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there was insufﬁcient information to give an overall risk of
bias assessment [Mehta (unpublished)] (RR = 0.51,
I2 = 0%, P= 0.68). The intervention effect was unchanged
when the analysis excluded two cross-sectional studies
[34,56] that reported baseline measures of effect only
(3367 participants, RR = 0.51, I2 = 0.0%, P = 0.73).
The intervention effect strengthened when estimates from
four unpublished data sources [Bruneau (unpublished),
Mehta (unpublished), Maher (unpublished), Judd (unpub-
lished)] were excluded (RR = 0.42, I2 = 0%, P = 0.96).
The intervention effect weakened slightly, and heterogene-
ity increased if all unadjusted estimates were pooled from
16 studies (10647 participants, RR = 0.57, I2 = 32.4,
P = 0.09 (Supporting information, Figs S1–S4).
We found no evidence that effectiveness varied by
geographical region (Fig. 2) or study design. We did ﬁnd
evidence of differential impact in the proportion of female
participants in the sample. With each 10% increase of
female participants in sample, the effect of intervention
exposure was reduced (ratio of RRs = 1.59) (Table 2).
High coverage of needle and syringe programmes
Five studies (3530 participants) reported adjusted
measures of high NSP coverage compared to no or low
NSP coverage and HCV incidence [27,29,33,56],
including one unpublished data set [Bruneau (unpub-
lished)]. Random-effect meta-analysis showed weak evi-
dence of an effect of high coverage of NSP on the
reduction in the risk of HCV infection (RR= 0.79) and high
heterogeneity between studies (I2 = 77%, P = 0.002).
Random-effects meta-analysis of seven studies (6455 par-
ticipants) that presented unadjusted estimates show that
the weak intervention effect was unchanged (RR = 0.77,
I2 = 79%, P = 0.000001) (Fig. 3). Evidence of any
intervention effect became weaker after excluding the
unpublished data set [Bruneau (unpublished)] (RR = 0.77,
P < 0.001). No NSP studies were rated critical on the risk
of bias tool (Supporting information, Fig. S5).
High NSP coverage was associated with a 56%
reduction in HCV acquisition risk (RR = 0.44) with low
heterogeneity (I2 = 12.3%, P = 0.337) when pooling
unadjusted estimates from Europe, but no effect for North
America and high heterogeneity (RR = 1.58, I2 = 89.5%,
P = 0 < 0.001) (Fig. 3). This pattern was maintained in
the pooling of adjusted estimates, with a reduction
in HCV acquisition associated with high NSP coverage in
Europe (RR = 0.24) and low heterogeneity (I2 = 0,
P=0.66), but not in North America (RR= 1.58), and high
heterogeneity (I2 = 89.5, P < 0.001) (Fig. 4). The
meta-regression analysis also showed evidence of differen-
tial impact by region comparing North America with
Europe (ratio of RRs = 3.73, P = 0.06) (Table 2).
Univariable meta regression analysis also suggested someTa
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association between high coverage of NSPand study design
(ratio of RRs = 3.5, P-value = 0.087 comparing
cross-sectional with longitudinal study design); this was
reduced when adjusted for geographical region (ratio of
RRs = 1.7, P-value = 0.577). We found no evidence of
differential impact by proportion of female participants in
the sample, homelessness or experience of prison.
Combination interventions: OST and high/low NSP
Random-effects meta-analysis pooling adjusted measures
from three studies [12,56] [Bruneau (unpublished)]
(3241 participants) showed that combined use of OST
and high coverage of NSP was associated with a 74% risk
reduction in HCV acquisition (RR = 0.26, I2 = 80%
P = 0.007). This effect was maintained when pooling un-
adjusted measures from four studies (3356 participants,
RR = 0.29, I2 = 64.4% P = 0.038) (Fig. 5).
The effect of exposure to OST and low coverage of
NSP from pooling adjusted measures from two studies
(2956 participants) was weaker (RR = 0.87,
I2 = 36.0% P = 0.67). This effect remained unchanged
when pooling unadjusted measures from three studies
(3071 participants) (RR = 0.76, I2 = 29.6% P = 0.24)
(Fig. 6).
Publication bias
A funnel plot of 13 estimates (12 studies) and Egger’s
bias coefﬁcient (0.87, P = 0.106) suggested no
evidence of publication bias in studies of current OST
exposure. A funnel plot of ﬁve estimates (ﬁve studies)
and Egger’s bias coefﬁcient (1.65, P = 0.54) suggested
little evidence of publication bias in studies of high NSP
coverage, although this analysis included only ﬁve studies
and may be under-powered (Supporting information, Figs
S6,S7).
Quality of evidence
Evidence for current use of OST is considered to be low
quality because it was derived from observational studies
with serious risk of bias. Evidence for combined use of
OST and NSP was also considered to be low quality.
Evidence for the effect of NSP was judged to be very low
quality (because of the high heterogeneity and smaller
Figure 2 Impact of current use of opioid substitution therapy (OST) versus no OST on hepatitis C virus (HCV) incidence from studies adjusted for
confounders and stratiﬁed by region [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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effect size), according to the GRADE criteria [23]. These are
reported in detail in the Cochrane Review [21].
DISCUSSION
Main ﬁndings
Opioid substitution treatment (OST) is associated consis-
tently with an average 50% reduction in the risk of new
HCV infections among PWID. The combined use of
high-coverage NSP with OST is associated with an average
reduction in risk of HCV infection by 74%. There is weaker
evidence that high coverage of NSP is associated with a
reduction in risk of new HCV infections globally. There
were no trials identiﬁed in the review. The majority of the
observational studies were assessed to be at severe or
critical risk of bias, and the strength of the evidence gener-
ated was low in the case of OST and very low for NSP [21].
Strengths and limitations
The two key limitations of the review are heterogeneity
in measurement of exposure to NSPs and confounding.
Consistent measures of NSP exposure through coverage
of injections by clean needles and syringes were used
throughout the European studies [12,29,32] [Hope
(unpublished)], whereas the North American studies drew
upon varied deﬁnitions of NSP use that focused on
frequency of attendance at NSPs [27,33] [Bruneau
(unpublished)]. The measure of 100% NSP coverage
corresponds to the situation where a person reports that
Figure 3 Impact of high-coverage needle and syringe programmes (NSP) versus no/low coverage on hepatitis C virus (HCV) incidence from
pooling unadjusted measures by region [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
Figure 4 Impact of high-coverage needle and syringe programmes (NSP) versus no/low coverage on hepatitis C virus (HCV) incidence from studies
adjusted for confounders and by region [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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they receive sufﬁcient or a greater number of sterile
syringes per reported injecting frequency, and is found
in sites which allow PWID to collect a large number of
syringes or attend very regularly, rather than in sites
which adopt a more restricted form of exchange. It is also
possible that the population exposed to 100% coverage
are more compliant than the comparison group in terms
of regular attendance and uptake of needles and syringes.
However, we cannot assume that they necessarily use all
needles and syringes obtained, as HCV transmission still
occurs in this population. Inconsistencies in NSP
measurement contributed to heterogeneity observed
among studies (I2 = 77%, P = 0.002), while differences
in study design, exposure measurement and patterns of
injecting may have contributed to the lack of effect of
NSPs on HCV transmission observed in North America.
The European deﬁnition of coverage may include needles
and syringes obtained from pharmacies, secondary
distribution via friends or via outreach, whereas the
North American deﬁnition is speciﬁc to ﬁxed-site NSP
use. In reality, PWID may obtain needles and syringes
from multiple sources and, as a consequence, use NSPs
less frequently for social support, HIV/HCV testing and
counselling and other specialist advice. These additional
Figure 5 Impact of opioid substitution therapy (OST) combined with high-coverage needle and syringe programmes (NSP) from studies adjusting
for confounders and all pooled estimates [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
Figure 6 Impact of opioid substitution therapy (OST) combined with low-coverage needle and syringe programmes (NSP) from studies adjusting
for confounders and all pooled estimates [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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services are essential to prevent the spread of blood-borne
viruses and reduce inequalities in health over time [57],
but the immediate effect on HCV incidence may be difﬁ-
cult to assess where measurement of exposure does not
capture uptake of sterile needles and syringes from other
sources. Measurement of NSP use that focuses on needles
and syringes without taking into account acquisition of
other drug preparation equipment from NSPs may also
have contributed to the lack of an association in some
settings, particularly in the United States, where almost
half of HCV seroconversions have been attributed to the
shared use of cookers (spoons) and cottons [5]. It is also
hypothesized that less frequent use of NSPs and lack of
federal funding for NSPs in the United States has resulted
in lower coverage among PWID overall, which may mask
an intervention effect, although in cities where the
studies took place coverage is not as low as for the
United States overall [58,59]. The higher proportion of
stimulant injectors in US studies also may contribute to
lower impact. Meta-regression analysis suggested no
differential impact between intervention effect and study
design for current use of OST, but suggested that
longitudinal studies of NSP found a lower effect than
cross-sectional studies which were associated with
European settings.
The control of confounders was limited and inconsis-
tent across the studies. However, synthesized effect
estimates for OST and combined effect of OST and
high-coverage NSP were consistent throughout multiple
studies and maintained between analyses that adjusted
for confounders and those that did not, suggesting the
variation did not affect the results. We cannot rule out
the effect of residual confounding on NSP—especially for
the lack of association between NSP use and HCV from
studies in North America. For example, it has been shown
that people who attend NSPs regularly in North America
also report greater injecting risk behaviours and other
social vulnerabilities (including sex work or homelessness),
and that after adjustment for these factors any positive
association between HCV or HIV transmission and NSP
attendance is reduced [60,61].
An additional limitation is that the GRADE criteria used
by Cochrane assess automatically evidence from observa-
tional studies as low quality [23]. The merits and limita-
tions of using Cochrane Reviews and GRADE criteria in
developing guidelines in the addictions ﬁeld has been
discussed recently [62], alongside a recognition for the
need to separate out the quality of the evidence from the
strength of the ensuing recommendation [63]. We agree
that this is an important distinction to make when examin-
ing the effect of interventions where there is no experimen-
tal evidence, and it is not ethical to conduct randomized
controlled trials. Observational studies can give misleading
results, and in some notable examples have been shown to
be false when compared to evidence from randomized trials
[64]. Nonetheless, consideration of other criteria for
assessing quality of evidence may be needed—such as size
of effect, consistency across sensitivity analyses, supporting
evidence, and use of instrumental variables to test for con-
founding [23].
Other evidence
This is the ﬁrst global quantitative systematic review of the
effectiveness of OST and NSP on reducing HCV, building
upon an earlier narrative review that OST and NSP reduce
injecting risk and global reviews on HIV [14,16,17]. Our
ﬁndings corroborate a pooled analysis, which suggested
that receiving OST and high coverage of NSP can reduce
HCV infection risk alone, but is greater in combination
[20]. Our ﬁndings suggested a stronger effect of high NSP
coverage in Europe, but no effect in North America. This
corroborates ﬁndings from another review that found
increased risk of seroconversion associated with NSP
attendance that relied predominantly upon evidence from
North America [19]. Meta-regression analysis suggested
evidence of a differential impact of OST by the proportion
of female participants in the sample, with the effectiveness
of the intervention reduced by 59% with every 10%
increase in female participants. This corroborates other
evidence that women are at increased risk of acquiring
hepatitis C compared to men and may have poorer access
to OST, possibly as a result of services not taking into
account gender-speciﬁc needs or being tailored towards
men [65–67].
Implications
Given the low quality of evidence for NSP, there is an
urgent need to improve transparency and consistency in
reporting of observational studies in order to support future
natural experiments and systematic reviews measuring
the impact of the intensity of intervention coverage upon
HCV and other outcomes. The development of improved
and consistentmeasures of NSP coverage, alongwithmore
consistent reporting of the conduct of studies to measure
exposure to NSPs and the assessment of confounders, are
needed to strengthen the evidence on the impact of NSP.
It has been noted that the greatest beneﬁts for people
with mental health and addiction problems including
PWID will be derived from providing better evidenced-
based care in relation to medication, substitution therapies
and abstinence programmes, aswell as addressing underly-
ing social problems arising from homelessness and
criminalization [68]. This is particularly relevant in low-
and middle-income countries, where resources may be
more restricted [62]. There is a wealth of evidence from
high-income settings of the beneﬁcial effects of OST in
OST and NSP to prevent HCV transmission 15
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reducing injection-related harms, including HIV and
bacterial infections, and improving access to services
[11,17,19,20,69,70]. However, global coverage of OST
remains very low, prohibited in the Russian Federation
and often restricted by age or duration of dependency prior
to treatment entry [71]. Our ﬁndings show the need to
remove restrictions on the concurrent use of both NSP
and OST to maximize reduction in HCV transmission. We
had insufﬁcient data to measure the impact of OST dosage
on HCV acquisition risk, but two studies that stratiﬁed by
dose showed that reduced risk was associated with high
doses of methadone (≥ 60 mg), pointing to the importance
of providing adequate dosages [12] [Bruneau (unpub-
lished)]. Distribution of needles and syringes through NSPs
needs to bemaintained alongside provision of OST. NSPand
OST services also need to develop gender-sensitive policies
and practices to encourage women to use services address-
ing gender-speciﬁc injecting related risk and other health
and social welfare needs. The potential role of the new era
of highly curative short-course direct-acting antiviral ther-
apies for HCV to reduce HCV transmission also needs to be
considered [72], and within this the importance of
ensuring equitable access of PWID to OST and NSPs that
can facilitate HCV testing and treatment. In summary,
our ﬁndings provide strong evidence that OST and in
combination with high-coverage NSP should be expanded
to prevent the transmission of HCV and reduce associated
morbidity and mortality.
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